Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients  

作　　者：Teresa Broquetas Montserrat Garcia-Retortillo Miquel Mico Lidia Canillas Marc Puigvehi Nuria Canete Susana Coll Ana Viu Juan Jose Hernandez Xavier Bessa JoseA Carrion 

机构地区：[1]Department of Gastroenterology,Liver Section,Hospital del Mar Medical Research Institute,Barcelona 08003,Spain [2]Departament of de Medicina,Universitat Autònoma de Barcelona,Barcelona 08003,Spain [3]Laboratori de Referencia de Catalunya,El Prat de Llobregat,Barcelona 08820,Spain

出　　处：《World Journal of Hepatology》2020年第11期1076-1088,共13页世界肝病学杂志（英文版）（电子版）

摘　　要：BACKGROUND Hepatitis B e antigen-negative chronic hepatitis B patients under nucleos(t)ids analogues(NAs)rarely achieve hepatitis B surface antigen(HBsAg)loss.AIM To evaluate if the addition of pegylated interferon(Peg-IFN)could decrease HBsAg and hepatitis B core-related antigen(HBcrAg)levels and increase HBsAg loss rate in patients under NAs therapy.METHODS Prospective,non-randomized,open-label trial evaluating the combination of Peg-IFN 180μg/week plus NAs during forty-eight weeks vs NAs in monotherapy.Hepatitis B e antigen-negative non-cirrhotic chronic hepatitis B patients of a tertiary hospital,under NAs therapy for at least 2 years and with undetectable viral load,were eligible.Patients with hepatitis C virus,hepatitis D virus or human immunodeficiency virus co-infection and liver transplanted patients were excluded.HBsAg and HBcrAg levels(log10 U/mL)were measured at baseline and during ninety-six weeks.HBsAg loss rate was evaluated in both groups.Adverse events were recorded in both groups.The kinetic of HBsAg for each treatment group was evaluated from baseline to weeks 24 and 48 by the slope of the HBsAg decline(log10 IU/mL/week)using a linear regression model.RESULTS Sixty-five patients were enrolled,61%receiving tenofovir and 33%entecavir.Thirty-six(55%)were included in Peg-IFN-NA group and 29(44%)in NA group.After matching by age and treatment duration,baseline HBsAg levels were comparable between groups(3.1 vs 3.2)(P=0.25).HBsAg levels at weeks 24,48 and 96 declined in Peg-IFN-NA group(-0.26,-0.40 and-0.44)and remained stable in NA group(-0.10,-0.10 and-0.10)(P<0.05).The slope of HBsAg decline in Peg-IFN-NA group(-0.02)was higher than in NA group(-0.00)(P=0.015).HBcrAg levels did not change.Eight(22%)patients discontinued Peg-IFN due to adverse events.The HBsAg loss was achieved in 3(8.3%)patients of the Peg-IFN-NA group and 0(0%)of the NA group.CONCLUSION The addition of Peg-IFN to NAs caused a greater and faster decrease of HBsAg levels compared to NA therapy.Side effects of Peg-IFN can limit its

关 键 词：Chronic hepatitis B Hepatitis B e antigen-negative Hepatitis B surface antigen Hepatitis B core-related antigen PEGYLATED-INTERFERON Nucleos(t)ids analogues©The Author(s)2020.Published by Baishideng Publishing Group Inc.All rights reserved 

分 类 号：R512.62[医药卫生—内科学]